Strides Pharma Science is currently trading at Rs. 903.40, up by 27.15 points or 3.10% from its previous closing of Rs. 876.25 on the BSE.

The scrip opened at Rs. 890.00 and has touched a high and low of Rs. 904.90 and Rs. 882.20 respectively. So far 1927 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1024.90 on 03-Nov-2025 and a 52 week low of Rs. 551.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 935.80 and Rs. 871.95 respectively. The current market cap of the company is Rs. 8169.73 crore.

The promoters holding in the company stood at 27.86%, while Institutions and Non-Institutions held 42.55% and 29.59% respectively.

Strides Pharma Science’s step‑down subsidiary -- Strides Pharma International AG (SPIAG) has entered into definitive agreements with Sandoz AG, Switzerland and its group entities (collectively referred to as ‘Sandoz’) for the acquisition and in‑licensing of a portfolio of branded generic products across Sub‑Saharan Africa (SSA).

The agreement spans four key markets - Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti‑infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding $1 million, reflecting their established brand equity and market demand. The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. To ensure the uninterrupted availability of these critical brands, Strides will also enter into a Manufacturing and Supply Agreement with Sandoz for their continued production and supply.

The initial consideration for the transaction is $12 million, payable at closing and is expected to be funded through internal accruals. The transaction is expected to close by the end of Q2FY27 (Quarter Ending September 30, 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions. With the combined strength of Strides’ existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the representable market.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.